Acute Phase Reactants in Patients with UPIA

Slides:



Advertisements
Similar presentations
Psoriatic Arthritis Emily Chang Morning Report August 14, 2009 August.
Advertisements

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,
What features of inflammatory arthritis aid a rheumatology nurse specialist in diagnosing inflammatory arthritis? G. Gormley 1*, K. Steele 1, D. Gilliland.
Drug Therapy for Rheumatoid Arthritis in Adults Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Wrap-Up and Post Course Self Assessment Dr. Diane Lacaille.
Achy shoulders and a very high CRP Sarah Tansley Rheumatology, Clinical Fellow.
What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.
Inflammatory Low Back Pain
A Guide to Rheumatoid Arthritis for Legislators Rheumatoid Arthritis Policy Resource Center.
Rheumatoid Arthritis Anila Malik GPVTS. Aims To cover the following: What is RA? Diagnostic criteria and clinical features Rheumatoid Factor Investigations.
Rheumatoid Arthritis(RA)
NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.
Diagnosing Mental Disorders- The Multiaxial Approach
EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.
Introduction to Healthcare and Public Health in the US The Evolution and Reform of Healthcare in the US Lecture b This material (Comp1_Unit9b) was developed.
Consultant Rheumatologist
Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.
High Impact Rheumatology For Primary Care Physicians.
Recommendation 4: Antibody Testing in Patients with UPIA.
3e Initiative 2009 How to investigate and follow-up Undifferentiated Peripheral Inflammatory Arthritis? Case 1.
Recommendation 1: Defining & Diagnosing UPIA. Learning Objectives State the definition of Undifferentiated Peripheral Inflammatory Arthritis (UPIA) Describe.
2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative An.
3e Initiative 2009 How to investigate and follow-up Undifferentiated Peripheral Inflammatory Arthritis? Case 2.
A NEW LOOK AT RA Interactive Hot Topics Series
Genetic Testing in Patients with UPIA
Radiographs in Patients with UPIA
SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden,
Professor, Rheumatology Division, Ankara University Medical Faculty
Rheumatoid Arthritis: Management and New Therapies
AS – the facts! Andrew Keat.
Disease Activity Scales in Patients with UPIA
From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.
3e Initiative 2009 How to investigate and follow-up Undifferentiated Peripheral Inflammatory Arthritis? Case 3 1.
New Criteria of RA Esraa Bukhari Houseofficer 29 Nov 2010.
Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1
FINAL Recommendations
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Diagnosing Rheumatoid Arthritis Early
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Wrap-Up and Post Course Self Assessment
Disease Activity Assessment Across the RA Continuum
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.
Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.
Window of Opportunity in RA
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
What on earth is Spondyloarthritis
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). Fatigue severity across.
EULAR-defined characteristics describing arthralgia at risk for RA
Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.
Clinical response in patients with early and established RA at month 24. *p
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.
Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.
Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Synovial Biopsy in Patients with UPIA
Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.
The Study Group aims to:
(A) JIA-ACR30/50/70/90 response rates by visit in part 1.
 Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.
Mean disease activity score based on a 28-joint count (DAS28 (ESR)) (A), Clinical Disease Activity Index (CDAI) score (B) and Simplified Disease Activity.
Multivariable model of adjusted
ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.
Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Presentation transcript:

Acute Phase Reactants in Patients with UPIA Recommendation 3: Acute Phase Reactants in Patients with UPIA Recommendation 3

Learning Objectives At the end of this section participants should be able to: Explain the role of acute phase reactants (APR) in predicting specific diagnoses in patients with UPIA Explain the role of APR in predicting prognosis in UPIA Describe the utility of repeating APR over time Learning Objectives At the end of this section participants should be able to: Explain the role of acute phase reactants’ (APR) in predicting specific diagnoses in patients with UPIA Explain the role of APR in predicting prognosis in UPIA Describe the utility of repeating APR over time

Recommendation 3 ESR and CRP should be performed at baseline in the work up for diagnosis [2b, B] and prognosis [2b, B] of UPIA and repeated when clinically relevant [5, D]. Recommendation 3 ESR and CRP should be performed at baseline in the work up for diagnosis [2b, B] and prognosis [2b, B] of UPIA and repeated when clinically relevant [5, D]. This recommendation had a strong agreement of 9.1/10. 91% of rheumatologists felt that this recommendation was already implemented in their practice.

Undifferentiated Arthritis Early stage of classifiable disease Part of an overlap of disease Partial form of a defined disease Disease of unknown origin UA envelops a heterogeneous group of recent onset arthritides that are not classifiable within established criteria sets such as those of the American College of Rheumatology (ACR) and The European League Against Rheumatism (EULAR). UA may represent an early stage of a classified form of arthritis that will eventually be definable; an overlap of more than one disease; a partial form of a defined disease; or a disease of unknown origin. UA overall has a better prognosis than RA as it encompasses a spectrum of self-limited disorders. As compared to RA, a patient with UA usually presents with fewer affected joints, less radiographic erosions, better functional ability, and a greater likelihood of being seronegative. Patients with UA are also less likely than patients with RA to require treatment that involves the use of corticosteroids (such as Prednisone) or DMARDs and a substantial proportion of UA patients remit spontaneously. Hitchon CA, Peschken CA, Shaikh S, El-Gabalawy HS. Early undifferentiated arthritis. Rheum Dis Clin N Am. 2005;31:605-626.

Predictors of Diagnosis and Prognosis Overlap UPIA Prognosis There is considerable overlap between diagnostic predictors and prognostic predictors, as a diagnosis infers prognostic information pertaining to that diagnosis.

ESR and CRP can predict diagnosis/prognosis in UPIA Some value -SpA x No value Prognosis -Persistence -X-ray progression -Structural damage -Functional disability ESR and CRP can help predict diagnosis/prognosis in UPIA. x = no studies available which address this question

From the systematic review, there was no data available concerning the fact whether acute phase reactants should repeated at certain time-intervals From the systematic review, there was no data available concerning the fact whether acute phase reactants should repeated at certain time-intervals

Repeat Acute Phase Reactants When Clinically Relevant Specific Diagnosis Specific Prognosis UPIA Self-Limited Arthritis Given the potential for evolution of UPIA over time, experts recommended that ESR/CRP should be repeated when clinically relevant. Time Given the potential for evolution of UPIA over time, experts recommended that ESR/CRP should be repeated when clinically relevant.

Other Acute Phase Reactants Evidence for other acute phase reactants – Interleukins, ferritin, MMP – were poor, and were not included in the recommendation Other Acute Phase Reactants Evidence for other acute phase reactants: Interleukins, ferritin, MMP were poor, and were not included in the recommendation

Summary Of the acute phase reactants, ESR and CRP have some utility in predicting a diagnosis of RA CRP has some prognostic value in predicting persistent arthritis, radiological progression and functional disability ESR and CRP should be repeated over time when clinically relevant Summary Of the acute phase reactants, ESR and CRP have some utility in predicting a diagnosis of RA CRP has some prognostic value in predicting persistent arthritis, radiological progression and functional disability ESR and CRP should be repeated over time when clinically relevant

References Baron M, Schieir O, Hudson M, Steele R, Kolahi S, Berkson L, et al. The clinimetric properties of the World Health Organization Disability Assessment Schedule II in early inflammatory arthritis. Arthritis Rheum. 2008 Mar 15; 59(3):382-390. Baron M, Steele R. Development of the McGill Range of Motion Index. Clin Orthop. 2007 Mar; 456:42-50. Bunn DK, Shepstone L, Galpin LM, Wiles NJ, Symmons DP. The NOAR Damaged Joint Count (NOAR-DJC): a clinical measure for assessing articular damage in patients with early inflammatory polyarthritis including rheumatoid arthritis. Rheumatology (Oxford). 2004 Dec; 43(12):1519-1525. Harwood RH, Carr AJ, Thompson PW, Ebrahim S. Handicap in inflammatory arthritis. British Journal of Rheumatology. 1996 Sep; 35(9):891-897.